Antiferritin IgG antibody for isotopic cancer therapy.
Radiolabeled antiferritin IgG will target ferritin-bearing tumors such as hepatoma, lung cancer, and neuroblastoma. In hepatoma 4 of 5 patients have had clinical remission of malignancy following intravenous doses up to 150 mCi of radiolabeled antiferritin IgG. The dosimetry of radiolabeled 131I-antiferritin reveals a 3-day effective half-life, low dose rate isotopic implant of tumors 5 rad/h, 2,000-3,000 rad to the tumor, and a tumor half-life of 7.7 days. The possibilities of this new cancer agent are discussed in regard to isotopes, greater antibody specificity, and methods of evaluation.
D000293:Adolescent; D000328:Adult; D000818:Animals; D000906:Antibodies / Q000276:immunology*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000276:immunology / Q000532:radiotherapy; D002986:Clinical Trials as Topic; D005260:Female; D005293:Ferritins / Q000276:immunology*; D006207:Half-Life; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology*; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000532:radiotherapy; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D009447:Neuroblastoma / Q000188:drug therapy* / Q000276:immunology / Q000532:radiotherapy; D011817:Rabbits / Q000276:immunology
D000906:Antibodies; D007074:Immunoglobulin G; D007457:Iodine Radioisotopes; D005293:Ferritins